Rheumatoid Arthritis

Counseling sessions and text messages can help patients with rheumatoid arthritis become more active.

Rheumatoid arthritis drug shows improvements over methotrexate and Humira in quality of life and physical function.

Patients with rheumatoid arthritis taking glucocorticoids in certain doses may have an increased risk of developing diabetes.

Baricitinib shows statistically significant improvements in quality of life and physical function.

Researchers evaluate patient preferences in the treatment of rheumatoid arthritis.

Remicade treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Specific venoms may lead to targeted therapies for conditions such as multiple sclerosis, rheumatoid arthritis, and other inflammatory disorders.

Survey indicates a disconnect among caregivers and the RA patients they treat.

Salt-inducible kinases found to limit the production of inflammatory molecules in human immune systems.

Baricitinib is a Janus-kinase inhibitor that interferes with intracellular enzymes in rheumatoid arthritis.

The cost of disease-modifying antirheumatic drugs for rheumatoid arthritis remains a concern.

Inflectra biosimilar treats conditions such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

Biosimilar infliximab-dyyb (Inflectra) treats a variety of autoimmune diseases.

Biosimilar infliximab-dyyb (Inflectra) treats a variety of autoimmune diseases, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.

Patients with conditions such as rheumatoid arthritis or Crohn’s disease found to benefit from at-home treatment.

Conditions such as rheumatoid arthritis and Crohn’s disease targeted by new antibody-based drug.

Serotonin or the compounds that activate serotonin receptors could decrease some RA symptoms.

Boosting serotonin may help regulate the immune response to rheumatoid arthritis.

Out-of-pocket spending has significant impact on prescription drug adherence in the treatment of RA through Medicare Advantage and Prescription Drug plan.

Sarilumab shows superiority to adalimumab treating the signs and symptoms of active rheumatoid arthritis.

Sanofi and Regeneron Pharmaceuticals announce results of phase 3 trial showing efficacy of sarilumab in improving the signs and symptoms of active rheumatoid arthritis.

MiRNA is a small non-coding RNA molecule that plays a role in the regulation of gene expression.

Researchers evaluate impact of medical cannabis on conditions such as rheumatoid arthritis, fibromyalgia and osteoarthritis.

There are several ongoing global phase 3 clinical trials for biosimilar adalimumab, which treats conditions such as rheumatoid arthritis, psoriatic arthritis, and Crohn's Disease.

Anti-inflammatory phytochemical in green tea shows promise in blocking the effects of RA.

Tofacitinib citrate (Xeljanz) is the first and only once-daily oral Janus kinanse inhibitor for the treatment of moderate-to-severe RA.

Tofacitinib citrate (Xeljanz) is an extended-release tablet for patients with moderate-to-severe rheumatoid arthritis.

Strong evidence suggests increased risk for respiratory, cardiovascular, and overall mortality for patients with RA.

The most commonly used biologic drugs to treat RA include etanercept, adalimumab, infliximab, and abatacept

Research seeks to to prevent the onset of an aggressive form of rheumatoid arthritis